JP2024511354A5 - - Google Patents
Info
- Publication number
- JP2024511354A5 JP2024511354A5 JP2023556938A JP2023556938A JP2024511354A5 JP 2024511354 A5 JP2024511354 A5 JP 2024511354A5 JP 2023556938 A JP2023556938 A JP 2023556938A JP 2023556938 A JP2023556938 A JP 2023556938A JP 2024511354 A5 JP2024511354 A5 JP 2024511354A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cell death
- inducing
- receptor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163448.0A EP4059495A1 (en) | 2021-03-18 | 2021-03-18 | Therapeutic combinations including inhibitors of the p2x4 receptor for treating and preventing proliferative disorders |
| EP21163448.0 | 2021-03-18 | ||
| PCT/EP2022/057133 WO2022195066A1 (en) | 2021-03-18 | 2022-03-18 | Therapeutic combinations including inhibitors of the p2x4 receptor for treating and preventing proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511354A JP2024511354A (ja) | 2024-03-13 |
| JP2024511354A5 true JP2024511354A5 (https=) | 2025-03-03 |
Family
ID=75108224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556938A Pending JP2024511354A (ja) | 2021-03-18 | 2022-03-18 | 増殖性疾患の治療および予防のためのｐ２ｘ４受容体の阻害剤を含む併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240075036A1 (https=) |
| EP (2) | EP4059495A1 (https=) |
| JP (1) | JP2024511354A (https=) |
| CN (1) | CN117062600A (https=) |
| CA (1) | CA3212209A1 (https=) |
| WO (1) | WO2022195066A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4542231A1 (en) * | 2023-10-16 | 2025-04-23 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Methods for identifying and stratifying cancers and cancer patients based on p2x4 receptor expression |
| CN120661500A (zh) * | 2025-08-25 | 2025-09-19 | 华中科技大学同济医学院附属协和医院 | 具有双靶点调控功能的gsk9027在治疗结直肠癌中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002152A1 (en) * | 2002-07-01 | 2004-01-01 | Isis Pharmaceuticals Inc. | Antisense modulation of P2X4 expression |
| CN100453118C (zh) * | 2005-04-06 | 2009-01-21 | 山东蓝金生物工程有限公司 | 一种含拓扑酶抑制剂的抗实体肿瘤药物组合物 |
| EP2641969A1 (en) | 2012-03-21 | 2013-09-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel therapeutic target for the prevention of tumour metastasis |
| WO2017070660A1 (en) | 2015-10-23 | 2017-04-27 | Baylor College Of Medicine | Targeting p2 purinergic receptors to treat hepatocellular carcinoma (hcc) |
-
2021
- 2021-03-18 EP EP21163448.0A patent/EP4059495A1/en not_active Withdrawn
-
2022
- 2022-03-18 JP JP2023556938A patent/JP2024511354A/ja active Pending
- 2022-03-18 US US18/280,370 patent/US20240075036A1/en active Pending
- 2022-03-18 WO PCT/EP2022/057133 patent/WO2022195066A1/en not_active Ceased
- 2022-03-18 CN CN202280021893.0A patent/CN117062600A/zh active Pending
- 2022-03-18 CA CA3212209A patent/CA3212209A1/en active Pending
- 2022-03-18 EP EP22717069.3A patent/EP4308098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Litmanovich et al. | The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice | |
| Li et al. | Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest | |
| Kutluk Cenik et al. | BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer | |
| Chai et al. | The effective combination therapies with irinotecan for colorectal cancer | |
| CN110478487B (zh) | 一种大环内酯化合物在逆转肿瘤多药耐药增强抗肿瘤疗效方面的应用 | |
| CN101743005B (zh) | 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法 | |
| KR20120004523A (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| Ozawa‐Umeta et al. | Curcumin β‐D‐glucuronide exhibits anti–tumor effects on oxaliplatin‐resistant colon cancer with less toxicity in vivo | |
| CN110573166B (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| CA3116234A1 (en) | Combination therapy utilizing dna alkylating agents and atr inhibitors | |
| JP2024511354A5 (https=) | ||
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| US11248016B2 (en) | Glycolipids and pharmaceutical compositions thereof for use in therapy | |
| UA124748C2 (uk) | N-заміщені індольні похідні | |
| Liu et al. | Bevacizumab‐enhanced antitumor effect of 5‐fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2‐specificity protein 1 pathway | |
| WO2013170637A1 (zh) | 芍药苷类化合物在制备抗肿瘤药物中的用途 | |
| JP2023024618A (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| Fukushima et al. | Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo | |
| Razi et al. | Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non–small cell lung cancer | |
| Wang et al. | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents | |
| Xia et al. | Synergistic Antitumor Effects of Anlotinib Combined with Oral 5‐Fluorouracil/S‐1 via Inhibiting Src/AKT Signaling Pathway in Small‐Cell Lung Cancer | |
| Li et al. | A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma | |
| GB2580963A (en) | Cancer therapies | |
| JP2007531728A5 (https=) | ||
| TW201929883A (zh) | Ｐａｒｐ抑制劑和溶瘤病毒用於製備抗腫瘤藥物之用途 |